Groundbreaking clinical trial demonstrates that FreeStyle Libre continuous glucose monitoring technology significantly improves glucose management in people with Type 2 diabetes using basal insulin therapy, with patients achieving better HbA1c reduction and more time spent in healthy glucose ranges compared to traditional fingerstick monitoring.
Abbott concludes 2025 with double-digit earnings growth and a powerful surge in Medical Device sales. With a new 2026 organic growth forecast of 6.5%–7.5% and a major entry into cancer diagnostics via the Exact Sciences acquisition, the healthcare leader signals a year of accelerated expansion ahead.
Abbott’s Tendyne™ device has secured FDA approval, revolutionizing mitral valve replacement. This minimally invasive system offers a crucial alternative for high-risk patients with severe mitral annular calcification, eliminating the need for open-heart surgery.
In addition, the research showed an 80% reduction in the hospitalization risk of cardiovascular disease in individuals with Type 1 diabetes who did not have a previous history of such illnesses.
In contrast to conventional cardiac ablation techniques, PFA therapy targets specific cardiac tissue regions with high-energy electrical pulses that result in irregular heartbeats.
AFib affects around 8 million Europeans over the age of 65, and this figure is anticipated to grow over the next 30 years.
